Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2023

Seagen - ADCs’ Potential Across Tumors

Panel Discussion and Audience Q&A

Date

22 Oct 2023

Session

Seagen - ADCs’ Potential Across Tumors

Topics

Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Presenters

All Speakers

Authors

J. Tabernero1, D. Planchard2, L.D. Locati3, T.B. Powles4, A. Speakers5

Author affiliations

  • 1 Medical Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 2 Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 3 Head And Neck Cancer Medical Oncology Unit, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, 20138 - Milan/IT
  • 4 Oncology Department, St. Bartholomew's Hospital - Barts Health NHS Trust, EC1A 7BE - London/GB
  • 5 ESMO - European Society for Medical Oncology, GX11 1AA - Lugano/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: Josep Tabernero

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

Closing Remarks

Presenter: Josep Tabernero

Session: Seagen - ADCs’ Potential Across Tumors

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.